Results 21 to 30 of about 36,553 (257)

Design and evaluation of a ZP3 peptide vaccine in a homologous primate model [PDF]

Molecular Human Reproduction, 1999
The concept of a safe, immunocontraceptive vaccine using the zona pellucida glycoprotein 3 (ZP3) as an immunogen has been marred by the appearance of ovarian dysfunction in several species. However, careful selection of epitopes on mouse ZP3 have demonstrated that it is possible to segregate contraceptive bone marrow-derived (B)-cell epitopes from the ...
M, Paterson, M R, Wilson, Z A, Jennings, M, van Duin, R J, Aitken   +4 more
openaire   +2 more sources

Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium

Vaccines, 2023
We investigated effectiveness of (1) mRNA booster vaccination versus primary vaccination only and (2) heterologous (viral vector–mRNA) versus homologous (mRNA–mRNA) prime-boost vaccination against severe outcomes of BA.1, BA.2, BA.4 or BA.5 Omicron ...
Marjan Meurisse, Lucy Catteau, Joris A. F. van Loenhout, Toon Braeye, Laurane De Mot, Ben Serrien, Koen Blot, Emilie Cauët, Herman Van Oyen, Lize Cuypers, Belgian Collaborative Group on COVID-19 Hospital Surveillance, COVID-19 Genomics Belgium Consortium, Annie Robert, Nina Van Goethem   +13 more
doaj   +1 more source

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study

Human Vaccines & Immunotherapeutics, 2023
The global supply of COVID-19 vaccines has been limited, and concerns have arisen about vaccine supply chain disruptions in developing countries. Heterologous prime-boost vaccination, which involves using different vaccines for the first and second doses,
Kriangkrai Tawinprai, Pawornrath Jungsomsri, Onnicha Pinijnai, Fahsiri Tavonvunchai, Anchisa Lievjaroen, Paphada Suwannaroj, Taweegrit Siripongboonsitti, Thachanun Porntharukchareon, Gaidganok Sornsamdang, Teerapat Ungtrakul   +9 more
doaj   +1 more source

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers

Vaccines, 2021
Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups.
Louise Benning, Maximilian Töllner, Asa Hidmark, Matthias Schaier, Christian Nusshag, Florian Kälble, Paula Reichel, Mirabel Buylaert, Julia Grenz, Gerald Ponath, Katrin Klein, Martin Zeier, Caner Süsal, Paul Schnitzler, Christian Morath, Claudius Speer   +15 more
doaj   +1 more source

Homologous and heterologous antibody responses to subunit influenza virus vaccine [PDF]

Journal of Hygiene, 1978
SummaryIn a group of 32 adult volunteers given subunit influenza virus vaccine containing 250 international units (i.u.) of A/Victoria/3/75, 250 i.u. of A/Scotland/ 840/74 and 300 i.u. of B/Hong Kong/8/73, there were substantial increases in the geometric mean homologous haemagglutination-inhibiting (HI) antibody titres.
B J, Feery, M G, Evered, K, Hayes
openaire   +2 more sources

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines

VirusDisease, 2022
Infectious bronchitis virus (IBV) has been frequently reported in chickens worldwide, including in the Eastern Region of Saudi Arabia (ERS). Several IBV outbreaks were recently reported in chickens despite the massive use of various vaccines. Based on partial sequencing of the S1 gene, at least three genotypes were reported (CK/CH/LDL/97I, IS/720/99 ...
Anwar A. G. Al-Kubati, Maged Gomaa Hemida, Abdullah I. A. Al-Mubarak   +2 more
openaire   +2 more sources

Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand

Infectious Disease Modelling, 2023
Low- and middle-income countries faced significant challenges in accessing COVID-19 vaccines during the early stages of the pandemic. In this study, we utilized an age-structured modeling approach to examine the implications of various vaccination ...
Suparinthon Anupong, Tanakorn Chantanasaro, Chaiwat Wilasang, Natcha C. Jitsuk, Chayanin Sararat, Kan Sornbundit, Busara Pattanasiri, Dhammika Leshan Wannigama, Mohan Amarasiri, Sudarat Chadsuthi, Charin Modchang   +10 more
doaj   +1 more source

HOMOLOGOUS BACTERIA AS A VACCINE IN TUBERCULOSIS.PRELIMINARY REPORT. [PDF]

JAMA: The Journal of the American Medical Association, 1907
The object of this investigation was to obtain from sputum a standardized vaccine for tuberculosis. The product is called tubercle vaccine, since it resembles closely an emulsion of a tubercle. PREPARATION OF SPUTUM. Fresh sputum was carefully washed through six normal salt solutions.
openaire   +2 more sources

In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant

Frontiers in Immunology, 2022
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and ...
Natalie Heinen, Corinna Sophie Marheinecke, Clara Bessen, Arturo Blazquez-Navarro, Arturo Blazquez-Navarro, Toralf Roch, Toralf Roch, Ulrik Stervbo, Moritz Anft, Carlos Plaza-Sirvent, Sandra Busse, Mara Klöhn, Jil Schrader, Elena Vidal Blanco, Doris Urlaub, Carsten Watzl, Markus Hoffmann, Stefan Pöhlmann, Matthias Tenbusch, Eike Steinmann, Daniel Todt, Daniel Todt, Carsten Hagenbeck, Gert Zimmer, Gert Zimmer, Wolfgang Ekkehard Schmidt, Daniel Robert Quast, Nina Babel, Nina Babel, Ingo Schmitz, Stephanie Pfänder   +30 more
doaj   +1 more source

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2

Frontiers in Immunology, 2022
BackgroundHeterologous vaccinations against SARS-CoV-2 with ChAdOx1 nCoV-19 and a second dose of an mRNA-based vaccine have been shown to be more immunogenic than homologous ChAdOx1 nCoV-19.
Robert Markewitz, David Juhl, Daniela Pauli, Siegfried Görg, Ralf Junker, Jan Rupp, Sarah Engel, Katja Steinhagen, Victor Herbst, Dorinja Zapf, Christina Krüger, Christian Brockmann, Frank Leypoldt, Justina Dargvainiene, Benjamin Schomburg, Shahpour Sharifzadeh, Lukas Salek Nejad, Klaus-Peter Wandinger, Malte Ziemann   +18 more
doaj   +1 more source